Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Nektar Therapeutics    NKTR

NEKTAR THERAPEUTICS

(NKTR)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

S&P 500 Movers: NKTR, COTY

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 10:36am EDT

In early trading on Tuesday, shares of Coty (COTY) topped the list of the day's best performing components of the S&P 500 index, trading up 13.8%. Year to date, Coty registers a 67.6% gain.

And the worst performing S&P 500 component thus far on the day is Nektar Therapeutics (NKTR), trading down 8.1%. Nektar Therapeutics is showing a gain of 29.5% looking at the year to date performance.

Two other components making moves today are Molson Coors Brewing (TAP), trading down 7.4%, and Brighthouse Financial (BHF), trading up 10.5% on the day.

© BNK Invest, source Videos

Stocks mentioned in the article
ChangeLast1st jan.
BRIGHTHOUSE FINANCIAL INC. -0.07% 41.19 Delayed Quote.35.14%
MOLSON COORS BREWING 3.33% 61.4 Delayed Quote.9.33%
NEKTAR THERAPEUTICS 1.57% 31.68 Delayed Quote.-3.62%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NEKTAR THERAPEUTICS
04/02NEKTAR THERAPEUTICS : Presents Preclinical Data on its Immuno-Oncology Pipeline ..
PU
04/01NEKTAR THERAPEUTICS : Vaccibody AS and Nektar Therapeutics Present New Preclinic..
PU
03/07Merck KGaA, Pfizer added to BioXcels pancreatic cancer deal
AQ
03/06NEKTAR THERAPEUTICS : to Webcast Presentation at the Cowen and Company 39th Annu..
PR
03/01NEKTAR THERAPEUTICS : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
03/01NEKTAR THERAPEUTICS : Presents Preliminary Immune Activation, Safety and Clinica..
PR
03/01NEKTAR THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
AQ
02/28NEKTAR THERAPEUTICS : Results of Operations and Financial Condition, Financial S..
AQ
02/28NEKTAR THERAPEUTICS : Reports Fourth Quarter and Year-End 2018 Financial Results
PU
02/27NEKTAR THERAPEUTICS : Announces Several Preclinical Data Presentations for its I..
PU
More news
Financials ($)
Sales 2019 121 M
EBIT 2019 -501 M
Net income 2019 -503 M
Finance 2019 1 671 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 31,7x
EV / Sales 2020 22,1x
Capitalization 5 516 M
Chart NEKTAR THERAPEUTICS
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEKTAR THERAPEUTICS
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 71,2 $
Spread / Average Target 125%
EPS Revisions
Managers
NameTitle
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
John Nicholson Chief Operating Officer & Senior Vice President
Gilbert M. Labrucherie Chief Financial Officer & Senior Vice President
Stephen K. Doberstein Chief Research & Development Officer
Sector and Competitors
1st jan.Capitalization (M$)
NEKTAR THERAPEUTICS-3.62%5 516
IQVIA HOLDINGS INC14.50%26 285
CELLTRION, INC.--.--%24 574
LONZA GROUP16.76%21 828
INCYTE CORPORATION16.31%15 847
EXACT SCIENCES CORPORATION46.13%11 596